Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,102.44 -712.12 (-1.83%) Hang Seng
17,936.12 -5.66 (-0.03%) FTSE 100
8,150.07 +3.21 (+0.04%) Bitcoin USD
65,387.81 -1,206.79 (-1.81%) CMC Crypto 200
1,368.56 -19.60 (-1.41%)
JNJ Sep 2024 80.000 call
| Previous close | 74.55 |
| Open | 74.55 |
| Bid | 64.25 |
| Ask | 68.20 |
| Strike | 80.00 |
| Expiry date | 2024-09-20 |
| Day's range | 74.55 - 74.55 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
PR NewswireSubcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
Johnson & Johnson (NYSE: JNJ) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) for all currently approved or submitted indications of intravenous (IV) RYBREVANT® (amivantamab-vmjw) in certain patients with non-small cell lung cancer (NSCLC).
PR NewswireLate-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the Phase 2 DAHLIAS dose-ranging study of nipocalimab in adult patients living with Sjögren's disease (SjD). Response was demonstrated as early as Week 4 and continued to increase throughout the 24-week treatment period compared with patients recei
ZacksJohnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
